Beyond Air (XAIR) Aperçu de l'action
Beyond Air, Inc. est une entreprise spécialisée dans les dispositifs médicaux et les produits biopharmaceutiques, qui a franchi le cap de la commercialisation. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 1/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
+ 1 plus de risques
XAIR Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Beyond Air, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$3.09 |
| Plus haut sur 52 semaines | US$55.60 |
| Plus bas sur 52 semaines | US$3.06 |
| Bêta | 0.13 |
| Variation sur 1 mois | -38.69% |
| Variation sur 3 mois | -62.22% |
| Variation sur 1 an | -93.07% |
| Variation sur 3 ans | -99.71% |
| Variation sur 5 ans | -99.90% |
| Évolution depuis l'introduction en bourse | -99.88% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Sep 08
XAIR: Reverse Split And Gen 2 Approval Could Unlock Recurring Revenue Upside
Analysts recently reset their fair value estimate for Beyond Air from $280 to $20, citing new coverage that highlights the potential for LungFit driven recurring revenue and an updated P/E based framework tied to anticipated Gen 2 device approval and a refreshed management strategy. Analyst Commentary Recent Street research on Beyond Air focuses heavily on the potential of the LungFit platform and how it could influence valuation, growth in recurring revenue, and execution risk around upcoming product milestones.Mise à jour du récit • Aug 11
XAIR: Reverse Stock Split Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Beyond Air from $160 to $280, citing updated assumptions around the discount rate, revenue growth, and profit margin in their pricing models. What’s in the News for Beyond Air Beyond Air plans a 1-for-20 reverse stock split, with the board approving the ratio on June 18, 2026, after stockholders authorized a potential range between 1-for-2 and 1-for-20 at a special meeting.Recent updates
Mise à jour du récit • Sep 08
XAIR: Reverse Split And Gen 2 Approval Could Unlock Recurring Revenue Upside
Analysts recently reset their fair value estimate for Beyond Air from $280 to $20, citing new coverage that highlights the potential for LungFit driven recurring revenue and an updated P/E based framework tied to anticipated Gen 2 device approval and a refreshed management strategy. Analyst Commentary Recent Street research on Beyond Air focuses heavily on the potential of the LungFit platform and how it could influence valuation, growth in recurring revenue, and execution risk around upcoming product milestones.Mise à jour du récit • Aug 11
XAIR: Reverse Stock Split Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Beyond Air from $160 to $280, citing updated assumptions around the discount rate, revenue growth, and profit margin in their pricing models. What’s in the News for Beyond Air Beyond Air plans a 1-for-20 reverse stock split, with the board approving the ratio on June 18, 2026, after stockholders authorized a potential range between 1-for-2 and 1-for-20 at a special meeting.Mise à jour du récit • Jul 27
XAIR: Reverse Stock Split And Listing Compliance Will Support Future Upside
Analysts have reset their fair value estimate for Beyond Air to $160.00, reflecting updated assumptions for revenue growth, profit margins and the removal of the future P/E input in their valuation framework. What’s in the News for Beyond Air Beyond Air plans either a 1-for-20 reverse stock split or a significant stock dividend, scheduled for July 13, 2026, according to a key corporate actions update.
Mise à jour du récit • Jul 13
XAIR: Reverse Split Plan Will Set Stage For Future Upside
Analysts have adjusted their price target for Beyond Air from $14.00 to $280.00, citing updated assumptions on discount rate, revenue growth, profit margin, and future P/E used in their valuation analysis. What’s in the News for Beyond Air Beyond Air plans a 1-for-20 reverse stock split or significant stock dividend, expected to take effect on July 13, 2026, according to company disclosures.Mise à jour du récit • Jun 17
XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future Upside
Analysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.Mise à jour du récit • Jun 03
XAIR: Future Hospital Access Agreement Will Support Long Term Upside Potential
Analysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.
Mise à jour du récit • May 06
XAIR: Later FDA Decision Will Still Drive Key Future Inflection
Narrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.Mise à jour du récit • Apr 21
XAIR: Later Regulatory Decision Will Still Support Long Term Upside Potential
Analysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.Mise à jour du récit • Apr 07
XAIR: Later FDA Decision Will Still Unlock Key Future Inflection
Narrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.Mise à jour du récit • Mar 24
XAIR: Extended FDA Timeline Will Still Set Up Key Future Inflection
Analysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.Mise à jour du récit • Mar 10
XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential Upside
Analysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.Mise à jour du récit • Feb 23
XAIR: Later FDA Decision Will Still Support Long Term Upside Potential
Analysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system. Analyst Commentary Bullish Takeaways Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.Mise à jour du récit • Feb 09
XAIR: Bullish Coverage And New Capital Raise Will Support Future Upside
Analysts now see Beyond Air's fair value holding at $6.00 per share, with a slightly higher discount rate and modestly adjusted revenue growth, profit margin, and future P/E assumptions following fresh bullish coverage that supports a constructive long term thesis on the stock. Analyst Commentary Recent coverage frames Beyond Air as a higher risk, higher reward idea, with the current fair value estimate of US$6.00 per share sitting against a backdrop of both optimism and clear caution.Mise à jour du récit • Jan 25
XAIR: Expanded Distribution And Fresh Capital Will Support Future Upside
Analysts have kept their fair value target for Beyond Air steady at US$6.00, while adjusting their models to reflect updated assumptions on discount rate, revenue growth, profit margin and future P/E following recent bullish Street research coverage. Analyst Commentary While the latest Street coverage has been supportive, some bearish analysts continue to flag risks that they believe are not fully captured in the current US$6.00 fair value estimate.Mise à jour du récit • Jan 11
XAIR: Expanded Global Distribution And Recent Financing Will Support Future Upside
Analysts have revised their price target for Beyond Air to US$6.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E multiples, which leaves the fair value estimate unchanged at US$6.00. What's in the News Beyond Air updated its earnings guidance for the fiscal year ending March 31, 2026, with revenue now guided to a range of US$8 million to US$10 million (Corporate guidance).Mise à jour du récit • Dec 26
XAIR: Expanded Global Distribution And New Financing Will Support Upside Potential
Analysts have modestly raised their price target on Beyond Air to reflect a slightly higher long term growth outlook and valuation multiple, while incorporating a more conservative discount rate and largely unchanged profit margin assumptions. What's in the News Signed multiple new international distribution agreements for LungFit PH across Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total coverage to 39 countries and over three billion people (Key Developments).Mise à jour du récit • Dec 12
XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside Potential
Analysts have raised their price target on Beyond Air to 6.00 dollars from 5.00 dollars, citing slightly stronger expected revenue growth, modestly improved profit margins, and a higher anticipated future price to earnings multiple despite a higher discount rate. What's in the News Chief Financial Officer Doug Larson has resigned to pursue another opportunity and will remain in his role until December 5, 2025.Mise à jour du récit • Nov 01
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
Analysts have modestly maintained their price target for Beyond Air at $12.33 per share. They cite steady expectations around revenue growth and profit margins, even though there have been minor adjustments to other financial assumptions.Mise à jour du récit • Oct 18
Global Expansion And Next-Generation Respiratory Care Will Transform Markets
Analysts have raised their price target for Beyond Air from $11.20 to $12.33, reflecting improved revenue growth expectations and a notable increase in projected profit margins. What's in the News The global distribution network for LungFit PH has been expanded, with new agreements in Japan, South Korea, Costa Rica, Guatemala, and El Salvador.Mise à jour du récit • Sep 04
Global Expansion And Next-Generation Respiratory Care Will Transform Markets
With minimal changes in both the discount rate and future P/E, Beyond Air’s consensus analyst price target remained effectively unchanged at $11.20. What's in the News Expanded global LungFit PH distribution network to 34 countries, including new agreements in Japan (with AMCO), South Korea, Costa Rica, Guatemala, and El Salvador.
Nouveau récit • Apr 14
The Next-Generation LungFit PH System Will Open New Markets
International revenue could significantly impact growth due to CE Mark approval and distribution partnerships, especially in the EU.Rendement pour les actionnaires
| XAIR | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -3.4% | 1.6% | -0.2% |
| 1Y | -93.1% | -16.2% | 12.1% |
Rendement vs Industrie: XAIR a sous-performé le secteur US Medical Equipment qui a rapporté -16.2 % au cours de l'année écoulée.
Rendement vs marché: XAIR a sous-performé le marché US qui a rapporté 12.1 % au cours de l'année écoulée.
Volatilité des prix
| XAIR volatility | |
|---|---|
| XAIR Average Weekly Movement | 16.4% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: Le cours de l'action de XAIR a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de XAIR a diminué de 26% à 16% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2011 | 54 | Bob Goodman | www.beyondair.net |
Beyond Air, Inc. est une société spécialisée dans les dispositifs médicaux et les produits biopharmaceutiques, dont les activités ont atteint le stade commercial. Elle opère à travers ses divisions Beyond Air, Beyond Cancer et NeuroNos. La société propose Lungfit PH pour le traitement de l’hypertension pulmonaire persistante du nouveau-né.
Beyond Air, Inc. Résumé des fondamentaux
| XAIR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$2.96m |
| Bénéfices(TTM) | -US$33.49m |
| Recettes(TTM) | US$7.69m |
0.4x
Ratio P/S-0.1x
Ratio P/ELe site XAIR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| XAIR compte de résultat (TTM) | |
|---|---|
| Recettes | US$7.69m |
| Coût des recettes | US$7.37m |
| Marge brute | US$321.00k |
| Autres dépenses | US$33.81m |
| Les revenus | -US$33.49m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -34.97 |
| Marge brute | 4.18% |
| Marge bénéficiaire nette | -435.71% |
| Ratio dettes/capitaux propres | 788.9% |
Quelles ont été les performances à long terme de XAIR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/20 15:58 |
| Cours de l'action en fin de journée | 2026/09/18 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Beyond Air, Inc. est couverte par 7 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |
| Justin Walsh | JonesTrading Institutional Services, LLC |